Kyung-Hoon Kim

Opiranserin (VVZ-149): what’s new in analgesics

cannot be fully anticipated. The major clinical concern is that opiranserin cannot be added to disposable intravenous patient-controlled analgesia devices due to their limited volume. Repeated administration may accumulate its active metabolite, VVZ-368 (N-desmethyl-VVZ-149).